What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYS6041: RP2D dose, ivgtt, Q3W Enlonstobart:360mg, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W”In the company’s words, NCT07714668 on ClinicalTrials.gov
- Main trialPhase 2
- “This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.”In the company’s words, NCT07714668 on ClinicalTrials.gov
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up2
- 28 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Apr 2028 | A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | |
| Phase 1/2Recruiting | 28 Mar 2027 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026